The ciliopathies are a collection of disorders with overlapping clinical manifestations that include renal cystic disease, polydactyly, retinal degeneration and defects of the central nervous system[@R1], and provide a useful model to investigate both the effects of variation at a single locus and the potential epistatic interactions between alleles at functionally related loci. This is because several ciliopathy-causing genes can either cause a distinct recessive form of ciliary disease or contribute modulators of penetrance and expressivity. In some instances, multiple allelism at a single locus can partially explain phenotypic variability. For example, null mutations in *NPHP3* cause MKS[@R2], while hypomorphic *NPHP3* alleles cause Nephronophthisis (NPHP)[@R3]. Similarly, hypomorphic *CEP290/NPHP6* mutations are observed frequently in Leber congenital amaurosis (LCA) in both humans and in a mouse model[@R4],[@R5], whereas loss-of-function mutations lead to a constellation of ciliopathies that include MKS, NPHP, Bardet-Biedl Syndrome (BBS) and JBTS[@R6]-[@R9] without a clear explanation for the phenotypic variation.

Consistent with the suggestion of second-site modifiers, several alleles are reported to modify ciliary phenotypes; a hypomorphic mutation in *MGC1203* contributes to the overall penetrance and expressivity of BBS[@R10], while heterozygous variants in *CEP290* and *AHI1* contribute to the phenotypic severity and pleiotropy of NPHP[@R11]. Finally, likely additive effects between alleles in *bona fide* BBS and MKS loci produce hybrid phenotypes of the two clinical entities[@R7].

A paradigm emerging from the above studies is that genes mutated in one ciliopathy may contribute alleles across the entire clinical spectrum and that the assessment of total mutational load across the ciliary proteome[@R12],[@R13] will help dissect phenotypic causality and variability. Towards this end, we have initiated two complementary strategies -- interactome studies on ciliary proteins and medical resequencing of known ciliopathy genes across a cohort of patients with diverse phenotypes (MKS and JBTS as severe, BBS as intermediate, NPHP and LCA as mild).

We first investigated *RPGRIP1L*, under the hypothesis that in addition to its association with MKS and JBTS[@R14],[@R15], it might also contribute alleles to other ciliary disorders. We screened 166 unrelated patients of northern European descent (17 MKS, 15 NPHP (with and without extra-renal phenotypes), 34 BBS, 100 LCA) and discovered 10 different novel nonsynonymous changes in 24 individuals ([Table 1](#T1){ref-type="table"}). We also detected two different common variants G1025S (rs2111119) and D1264N (rs3213758), both of which are present at similar allele frequencies when compared across our ciliopathy cohort, a cohort of 96 control individuals of northern European descent, and 60 CEPH controls from HapMap (data not shown).

None of the observed alleles are sufficient to explain disease manifestation under a Mendelian model. However, most alleles were either unique to our patient population, or were enriched compared to ethnically matched controls, and mapped within known functional domains of RPGRIP1L ([Table 1](#T1){ref-type="table"}; [Suppl. Fig. 1](#SD1){ref-type="supplementary-material"}).

However, the rarity of most alleles precluded us from delineating their impact on the clinical phenotypes. One notable exception, A229T, is sufficiently frequent to empower such a study. To assess allele neutrality without a preconceived model of inheritance, we performed Transmission Disequilibrium Testing (TDT); we screened 145 BBS families for which DNA was available from both parents. Focusing on families in which only one of the two parents was an A229T heterozygote, we identified 18 informative trios and detected significant over-transmission of the threonine-encoding allele in patients (15/18 transmissions; 83.3%, p\<0.01).

Despite the modest number of trios, the TDT suggested that the A229T change is not neutral. To probe this possibility further, we re-evaluated our original resequencing data. We found a surprising enrichment of the 229T allele in northern European patients in whom retinal degeneration is mandatory for diagnosis, such as in BBS or Senior-Loken Syndrome (SLS) (5.9%; 4/68 chromosomes, and 15%; 3/20 chromosomes respectively; [Table 1](#T1){ref-type="table"}, compared to a 2.8% allele frequency in unaffected northern Europeans; [Table 2](#T2){ref-type="table"}). We therefore wondered whether this variant might contribute to the retinal defect, which is a frequent, but not ubiquitous, ciliopathy phenotype. If this is true, then comparisons between NPHP (no retinal degeneration) versus SLS cohorts (NPHP and retinal degeneration) should be informative. Even though each of these phenotypes is rare in the general population, we were able to study two northern European cohorts: 66 unrelated patients with isolated NPHP and 84 patients with SLS. Remarkably, 229T was absent from the NPHP group, but was detected at an allele frequency of 5.4% in SLS patients ([Table 2](#T2){ref-type="table"}). The small size of this cohort precluded meaningful statistical analysis. Nonetheless, these data suggested that the absence of 229T might have a protective effect from RP.

To investigate this possibility, we queried whether the 229T allele frequency is significantly different in a larger case-control cohort of northern European ciliopathy patients ([Suppl. Table 1](#SD1){ref-type="supplementary-material"}). We categorized our patients into two groups, with retinal phenotypes being the sole distinguishing factor. Both groups exhibited significantly different 229T allele frequencies compared to controls (n=3016 control alleles); the allele was absent from the non-retinal degeneration group (n=230 alleles; p=1.92E-03) but was enriched in the retinal degeneration group (combined: 4.5%, n=974 alleles, p=6.45E-03; [Table 2](#T2){ref-type="table"}). Furthermore, in agreement with our earlier data, we observed significantly different 229T allele frequencies between the non-retinal pathology and retinal degeneration ciliopathy groups (p=7.35E-05; [Table 2](#T2){ref-type="table"}). To evaluate the statistical significance of our findings further, we performed permutation analyses where the observed genotypes in the entire sample were assigned randomly without replacement in the three groups (ciliopathy +RP, ciliopathy −RP, controls). After 10^7^ independent random assignments, we counted the number of times that the differences in minor allele frequency in each group matched or exceeded the actual differences. This study provided additional evidence that the association data did not occur by chance ([Table 2](#T2){ref-type="table"}). Importantly, we found A229T to be transmitted through at least three different haplotypes (three patients contained unique *RPGRIP1L* SNPs *in cis* with 229T), while the frequency of 229T was indistinguishable across cohorts collected at different sites ([Suppl. Table 1](#SD1){ref-type="supplementary-material"}), arguing against a stratification artifact.

Our genetic data suggest a role for 229T in the development of RP in ciliopathy patients. However, the low frequency of this allele in the population and its apparent modest effect in our cohorts limit the power of genetic studies. We therefore evaluated the potential consequences of A229T to protein function.

As a first test, we performed a genetic rescue experiment using an *in vivo* model. We have shown previously that suppression of ciliary and basal body proteins in zebrafish leads to measurable phenotypes in mid-somitic embryos, some of which are caused by defects in Wnt signaling[@R16],[@R17], a phenotype also observed in other experimental ciliopathy models[@R18]. The ability of human mRNA to rescue somitic phenotypes has proven useful for establishing the pathogenic potential of alleles by comparing the efficiency of rescue of wild type (wt) human messenger RNA (mRNA) compared to mRNA bearing the missense variant(s) under investigation[@R7]. We identified a single partial zebrafish transcript that, upon reciprocal BLAST analysis, showed the highest amino acid similarity between zebrafish and human (73% similarity, 55% identity), to which we designed a splice-blocking morpholino (MO). The MO was injected into wild-type (wt) embryos at the two-cell stage (50-100 embryos per injection) and scored at the eight to nine somite stage. Consistent with data from other ciliopathy genes[@R7],[@R10],[@R16],[@R17], we observed dose-dependent gastrulation defects that included a shortened body axis, thin somites with broad lateral extensions, minor kinking of the notochord, underdeveloped anterior structures and tail extension abnormalities, all of which enabled us to categorize embryos into two classes based on objective criteria (Class I or Class II; [Fig. 1a](#F1){ref-type="fig"}; [Suppl. Fig. 2a](#SD1){ref-type="supplementary-material"}). These phenotypes resulted from loss of *rpgrip1l*, since RT-PCR and sequencing analysis of embryos showed 10 ng of MO to cause ∼50% reduction of *rpgrip1l* mRNA ([Suppl. Fig. 2b](#SD1){ref-type="supplementary-material"}). Importantly, the phenotypes could be rescued by co-injection of 50 pg of wt human mRNA (embryos scored blind to injection cocktails; [Fig. 1b](#F1){ref-type="fig"}, [Suppl. Table 2](#SD1){ref-type="supplementary-material"}).

We therefore proceeded to compare the efficiency of rescue between human mRNA encoding each of 229A and 229T. In addition, we included two known pathogenic missense alleles, T615P and A695P, that cause JBTS[@R14],[@R15] as positive controls, as well as the neutral G1025S variant as a negative control. Embryos were co-injected with a cocktail of MO and each human mRNA (n=88-115 embryos per allele) and scored blind to the injection cocktail ([Suppl. Table 2](#SD1){ref-type="supplementary-material"}). We found that the 229T rescue gastrulation phenotype was significantly different from wt mRNA rescue (p\<0.0001; [Fig1b](#F1){ref-type="fig"}, [Suppl Table 2](#SD1){ref-type="supplementary-material"}). The assay was specific, since each of T615P and A695P were scored as pathogenic, but had no off-target effects; the rescue of the 1025S-encoding mRNA was indistinguishable from the 1025G message ([Fig1b](#F1){ref-type="fig"}).

To substantiate these assessments, we measured embryonic structures labeled *in situ* with *pax2*, *krox20*, and *myoD* riboprobes. On whole embryo flat-mounts age-matched to eight to nine somites, we calculated the ratio of the width (w) spanning the distal ends of the 5^th^ somites to the length (l) of the notochord as demarcated by adaxial cell labeling (n=8-20 embryos measured per variant). Consistent with our live embryo scoring, comparison of the mean w/l ratios between wt and mutant rescues indicated that both positive control alleles and A229T, but not G1025S, are pathogenic ([Fig. 1c, d](#F1){ref-type="fig"}; [Suppl. Table 3](#SD1){ref-type="supplementary-material"}).

As a third line of *in vivo* evidence, we examined 5-day *rpgrip1l* morphant larvae (n=52-78 embryos/injection). Consistent with other ciliopathy morphants[@R19], we observed tail extension abnormalities in 35% of *rpgrip1l* morphants, which was rescued by co-injection of wt human *RPGRIP1L* message ([Fig. 1e, f](#F1){ref-type="fig"}). However, mRNA encoding 229T was unable to efficiently rescue the tail phenotype (p=0.031), consistent with both the T615P and A695P rescues (p=0.001 and 0.004 respectively). These observations, in addition to the absence of tail phenotypes in morphants rescued with G1025S mRNA, substantiated further the specificity of our assay ([Fig. 1e, f](#F1){ref-type="fig"}).

We next turned to the question of why A229T might have the observed effect on the retinal degeneration phenotype. We noted that mutations in one of the NPHP genes, *NPHP5*, are also associated with an increased incidence of SLS; all tested patients with *NPHP5* null variants exhibit retinal degeneration compared to a 10% incidence of retinopathy in patients with mutations in other NPHP-associated genes[@R20]. NPHP5 interacts with RPGR[@R20], a ciliary protein mutated in 70-80% of X-linked RP and 20-25% of simplex RP[@R21]-[@R24]. We therefore hypothesized that RPGRIP1L might also interact biochemically with RPGR and that the A229T allele might have a measurable effect on the affinity of this interaction. As part of our ongoing efforts to understand the pathobiology of RPGR, we had performed yeast two-hybrid (Y2H) screens of human retinal cDNA as prey using full-length RPGR^ORF15^ as bait and identified the carboxyl-terminal domain of RPGRIP1L (RPGR-interacting domain; RID); this interaction was validated by known-bait and known-prey analysis using different domains of RPGR as bait ([Fig. 2a, b](#F2){ref-type="fig"}). To corroborate the findings, we generated an anti-human RPGRIP1L antibody ([Suppl. Fig. 3](#SD1){ref-type="supplementary-material"}) and performed co-immunoprecipitations (IP) using bovine retinal extracts. In reciprocal IP experiments with RPGRIP1L or RPGR antibody, we detected the expected bands on immunoblots corresponding to RPGR or RPGRIP1L, respectively ([Fig. 2c](#F2){ref-type="fig"}). Co-transfection of COS-1 cells followed by co-IP demonstrated that Xpress-tagged RPGR and GFP-RPGRIP1L proteins are part of the same complex ([Fig. 2d](#F2){ref-type="fig"}). We then tested A229T and three reported JBTS variants[@R14],[@R15] that are shown to be pathogenic in our zebrafish assay. Triplicate experiments showed that the GFP-tagged A229T mutant protein showed considerably lower (∼80%) ability to immunoprecipitate RPGR and has a profound effect on RPGR binding compared to the JBTS mutations ([Fig. 2e, f](#F2){ref-type="fig"}). We also found that RPGRIP1L localizes to the cilium and basal body of mouse IMCD3 cells and to the inner segment/connecting cilium of mouse photoreceptors ([Suppl. Fig. 4](#SD1){ref-type="supplementary-material"}), in the same spatiotemporal context as demonstrated previously for RPGR[@R4],[@R23],[@R24]. Hence, the abrogation of RPGRIP1L-RPGR interaction is likely to be relevant in photoreceptors.

Second-site modifications are emerging as prevalent phenomena in Mendelian disorders. For example, PLS3 is a protective modulator of SMN1 dysfunction associated with Spinal Muscular Atrophy (SMA)[@R25]; mutations in *CNTF* modify the age of onset in amyotrophic lateral sclerosis (ALS)[@R26], while a mutation in *MGC1203* can modify the global penetrance/expressivity in BBS[@R10]. However, the penetrance and expressivity of tissue-specific defects within the context of syndromic disease pose a considerable challenge, especially for alleles of modest frequency in the general population and modest effect on the phenotype, which cannot be captured by traditional population-based genetic tools. Our data suggest that, in patients of northern European descent, the presence of the 229T allele of RPGRIP1L has predictive value for retinal degeneration. It will be important to consider the nature and position of mutations at the primary locus, since A229T probably exerts its effect in the context of mutations in specific ciliopathy proteins that can complex with RPGR in the retina; this is consistent with the previously proposed poison model of genetic epistasis[@R27].

It is possible that some of the other alleles reported herein might also exhibit a similar effect; however, their rarity will necessitate the evaluation of larger cohorts. Notably, *in vivo* evaluation of each of the rare alleles using the zebrafish rescue assay suggested that most are pathogenic ([Table 3](#T3){ref-type="table"}, [Suppl. Table 2](#SD1){ref-type="supplementary-material"}, [Suppl. Table 3](#SD1){ref-type="supplementary-material"}, [Suppl. Fig 5](#SD1){ref-type="supplementary-material"}) and that they can potentially interact with alleles at various sites of the ciliopathy genetic spectrum ([Table 1](#T1){ref-type="table"}). Also, destabilization of the RPGRIP1L-RPGR complex is unlikely to be the sole cause of retinal degeneration. RPGRIP1L also associates with RPGRIP1 ([Fig. 2c](#F2){ref-type="fig"}), null mutations in which cause early-onset, severe retinal degeneration[@R28]. Three of the alleles found in our cohort, A1183G, R1236C and D1264Y map within the RPGRIP1-interacting domain of RPGRIP1L; hence, their contribution to disease might be mediated by loss of RPGRIP1 activity/function. Finally, RPGRIP1L and RPGR are members of a larger macromolecular complex whose composition and function will vary across tissue types and ciliary functions. Establishment of the content and the stoichiometry of such complex(es), coupled to the evaluation of ciliopathy alleles on the stability of the macromolecular complex in a tissue/function-dependent manner will enable the currently poor allelic stratification of variability in disease phenotypes.

Methods {#S1}
=======

Ciliopathy patients, controls, and mutational analysis {#S2}
------------------------------------------------------

Control DNAs were obtained from healthy individuals with no clinical ciliopathy criteria (retinal degeneration, polydactyly, renal abnormalities, mental retardation or other central nervous system defects) from four collection points ([Suppl. Table 1](#SD1){ref-type="supplementary-material"}). Blood samples were obtained following informed consent. We amplified the exon sequence and intron/exon junctions of *RPGRIP1L* (NM_015272) from DNA extracted from lymphoblast cell lines or lymphocytes according to standard protocols. PCR products were sequenced with BigDye Terminator v3.1 chemistry on an ABI 3100 or ABI 3730 (Applied Biosystems), sequences were analyzed with PolyPhred, and variants were confirmed by resequencing and visual assessment of chromatograms. Primer sequences and PCR conditions are available upon request.

Statistical analyses {#S3}
--------------------

We used plink v1.04 (<http://pngu.mgh.harvard.edu/purcell/plink/>) for TDT analysis in BBS trios, and the PEPI404x package for Fisher\'s exact test. All other analyses were performed in Microsoft Excel.

DNA constructs {#S4}
--------------

We generated full-length or specific domains of *RPGR* by PCR from retinal cDNA and subcloned them into the pcDNA 4 expression vector (Invitrogen). Full-length *RPGRIP1L* was amplified from human retinal cDNA, cloned into expression vector pEGFP-C1 (*in vitro* assays) or pCS2+ (*in vivo* assays) and confirmed by direct sequencing. Mutagenesis was performed using the QuickChange Site-Directed Mutagenesis kit (Stratagene), according to manufacturer\'s instructions.

Zebrafish embryo manipulation and morpholino injection {#S5}
------------------------------------------------------

A splice-blocking MO (Gene Tools) was diluted to appropriate concentrations in deionized, sterile water (2, 4, 6, 8, and 10ng/nl for the dose response, and 10ng/nl for rescue experiments) and was injected into wt zebrafish embryos at the two-cell stage as described[@R10]. To rescue the MO phenotype, we transcribed mRNA from linearized pCS2+-*RPGRIP1L* vector with the SP6 mMessage machine kit (Ambion). We carried out *in situ* hybridization on whole embryos fixed with 4% paraformaldehyde with riboprobes against *pax2*, *krox20*, and *myoD* using standard protocols. Images were captured at 10X magnification and measurements were taken of the width spanning the 5^th^ somites from the anterior end, and the length of the notochord as defined by *myoD* staining of adaxial cells. Embryos used for assessment of tail phenotypes at 5dpf were reared in 1-phenyl-2-thiourea (PTU)-treated embryo media, and anesthetized with Tricaine for imaging at 4X magnification. MO efficiency was determined by extracting total RNA from embryos with Trizol (Invitrogen) according to manufacturer\'s instructions. Oligo-dT-primed total RNA was reverse transcribed using SuperScriptIII reverse transcriptase (Invitrogen) and cDNA was subsequently PCR amplified and sequenced using standard procedures.

Yeast two-hybrid screen {#S6}
-----------------------

We carried out the yeast two-hybrid (Y2H) analysis using the Matchmaker Gal4-two hybrid system (Clontech), according to manufacturer\'s instructions. We amplified the full-length cDNA of mouse Rpgr^ORF15^ or its different domains and cloned into the bait vector pGBKT7. The adult human retinal cDNA library was cloned into the 'prey' pGADT7 vector (Clontech) and used for the screen. Known-bait and known-prey analysis was carried out as described[@R29].

Antibodies {#S7}
----------

Characterization of the ORF15^CP^ antibody has been described[@R24]. Anti-RPGRIP1L antibody was generated by immunizing rabbits with the human peptide ^1300^HALQSVYKQYRDDLE^1314^ (Yenzym). RPGRIP1 antibody was a gift from Dr. Tiansen Li (Harvard Medical School); Antibodies against Xpress-tag and acetylated α-tubulin were procured from Invitrogen and Chemicon, respectively.

Mammalian cell culture, transient transfection, co-immunoprecipitation (coIP) and immunolocalization {#S8}
----------------------------------------------------------------------------------------------------

We propagated COS-1 cells in DMEM plus 10%FBS, supplemented with Penicillin, Streptomycin and L-Glutamine. Co-IP experiments from retina and transfected cells have been described[@R24]. Immunolocalization studies in cells and in the retinal sections were carried out as reported previously[@R4],[@R30].
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![Functional assessment of the *RPGRIP1L* A229T variant *in vivo*\
**a**. Zebrafish embryos injected with *rpgrip1l* splice-blocking morpholino (MO) display gastrulation defects at the eight-nine somite stage; lateral and dorsal views of live embryos are shown. Embryos were categorized phenotypically based on the presence of a shortened body axis (anterior and posterior ends indicated with blue triangles) and small head/eyes only (magenta lines indicate eye size) (Class I; mild); or shortened body axis and small head/eyes in addition to at least one of the following: broad and thin somites (white line indicates somite span), notochord kinking, and tail extension defects (black asterisk) (Class II; severe).\
**b**. Live scoring of embryos co-injected with MO and human *RPGRIP1L* mRNA indicates that A229T is pathogenic in our assay as indicated by the comparison of WT rescue efficiency to mutant rescue efficiency. MO, morpholino alone; WT, wild-type human *RPGRIP1L* mRNA. Known JBTS mutations T615P and A695P are positive controls; neutral variant G1025S (rs2111119) is a negative control. Statistical significance (mutant rescue vs. WT rescue) is depicted as (\*\*\*), p\<0.0001 (χ^2^); see [Suppl Table 2](#SD1){ref-type="supplementary-material"} for all χ^2^ and p-values.\
**c**. Representative examples of whole-mount embryos hybridized *in situ* with *pax2*, *krox20*, and *myoD* riboprobes.\
**d**. Two-dimensional morphometric quantification of the efficiency of human *RPGRIP1L* mRNA to rescue *rpgrip1l* MO phenotypes. Whole embryos with eight-nine appreciable somites (n=8-20/injection) labeled with *pax2*, *krox20*, and *myoD* riboprobes were flat-mounted, photographed and measured in two dimensions. The width/length ratio was calculated as the width (w) spanning between the distal ends of the 5^th^ anterior somites (horizontal arrow in panel **c**) vs. the length (l) of the notochord as indicated by the staining of adaxial cells (vertical arrow in panel **c**). Statistical significance (mutant vs. WT rescue) is depicted as (\*), p\<0.05 and (\*\*\*), p\<0.0001 (two-tailed student\'s t-test); see [Suppl Table 3](#SD1){ref-type="supplementary-material"} for all p-values.\
**e**. *rpgrip1l* morphant larvae display tail development defects at 5 days post-fertilization (dpf). Morphant larva (MO) with tail curvature and posterior structural disorganization can be rescued efficiently with WT human *RPGRIP1L* mRNA, however *RPGRIP1L* message harboring the 229T encoding allele does not completely rescue the tail phenotype.\
**f**. Quantification of the efficiency of tail phenotype rescue in 5dpf larvae. Whereas WT *RPGRIP1L* message completely rescued the tail phenotypes, A229T as well as positive controls T615P and A695P result in the persistence of affected tail structures in injected larva. G1025S was used as a negative control. Statistical significance (mutant rescue vs. WT rescue) is depicted as (\*), p\<0.05 (χ^2^).](nihms-103218-f0001){#F1}

![RPGRIP1L interacts with RPGR and missense variant A229T abrogates this interaction\
**a**. Known-bait and known-prey analysis. Yeast two-hybrid analysis using indicated RPGR bait-encoding constructs and RPGRIP1L \[carboxyl-terminal (C) or full-length (FL)\] prey encoding constructs revealed interaction of RPGR exons 1-11 with carboxyl-terminal or full-length RPGRIP1L. Laminin was used as negative control, whereas p53/T-antigen (T-Ag) interaction served as a positive control.\
**b**. RPGR-RPGRIP1L interaction was validated further by examining the activation of the *LacZ* gene in the β-galactosidase assay corresponding to (**a**).\
**c**. Interaction of RPGR and RPGRIP1L *in vivo*. Bovine retinal extracts were subjected to immunoprecipitation (IP) using anti-RPGR, RPGRIP1, RPGRIP1L antibodies, normal immunoglobulin (IgG), or pre-immune serum (Pre-Imm). Precipitated proteins were analyzed by SDS-PAGE and immunoblotting (IB) using anti-RPGRIP1L (left) or RPGR-ORF15^CP^ antibody (right). Arrow (left) indicates RPGRIP1L-imunoreactive band and the straight line in the right panel depicts the RPGR isoforms pulled down by RPGRIP1L. Asterisk (\*) marks a non-specific immunoreactive band.\
**d**. RPGR-RPGRIP1L interaction in transfected cells. COS-1 cells were transiently transfected with constructs encoding Xpress-tagged RPGR, GFP-RPGRIP1L or Xpress-tag alone. Proteins were extracted and subjected to immunoprecipitation (IP) using the anti-GFP antibody. Precipitated proteins were analyzed by SDS-PAGE and immunoblotting using anti-Xpress antibody. Input lane contains 20% of the protein extract used for IP. Arrow indicates the Xpress-immunoreactive band.\
**e**. Interaction of RPGR with wild-type (WT) and mutant RPGRIP1L. COS-1 cells were transiently transfected with constructs encoding WT or mutant RPGRIP1L fused to GFP and Xpress-tagged RPGR. Panels 'a' and 'b' indicate the 20% of the GFP-RPGRIP1L and Xpress-RPGR input protein extract used for IP. Precipitation of GFP-RPGRIP1L using the GFP antibody was used as a positive control (panel 'c'). Association of wt and mutant GFP-RPGRIP1L with Xpress-RPGR is represented in Panel 'd'. T677I represents a *bona fide* pathogenic allele, but which likely does not contribute to retinal degeneration.\
**f**. Quantitative analysis of the band intensities are represented as percent of mutant RPGRIP1L immunoprecipitated by RPGR. Association of wt GFP-RPGRIP1L with RPGR was considered as 100%. The results represent an average of three independent experiments.](nihms-103218-f0002){#F2}

###### 

Total mutational load in northern European ciliopathy patients with *RPGRIP1L* variants

  -----------------------------------------------------------------------------------------------------------------
  Clinical\   Patient\     *RPGRIP1L*\   Allele\         Other Alleles   
  Diagnosis   ID           Alleles       Frequency in\                   
                                         Controls                        
  ----------- ------------ ------------- --------------- --------------- ------------------------------------------
  LCA         3184         S199G                         0/192           

  LCA         340          A229T                         84/3016         *RPGR:* I1148V het

  LCA         341          A229T         A229T           84/3016         *LCA5:* Q279X het

  LCA         1972         L546F                         0/192           

  LCA         1321         V647I                         0/192           *CRB1:* C948Y hom

  LCA         1378         T677I                         0/260           *RPGRIP:* R890X hom

  LCA         1380         T677I                         0/260           

  LCA         1617         R937L                         0/192           

  LCA         3182         A1183G                        4/192           *RPGR:* I1148V het

  LCA         3189         A1183G                        4/192           *RPGR:* I1148V het, N1081K het

  LCA         3181         D1264Y                        0/192           *RPGR:* I1148V het

  LCA         3187         D1264Y                        0/192           *RPGR:* I1148V het

  LCA         3192         D1264Y                        0/192           

  SLS         F259-II1     A229T                         84/3016         *NPHP5:* R364X het

  SLS         F848-II1     A229T                         84/3016         *NPHP5:* T627M het, *CEP290:* R1978X het

  SLS         F99-II1      A229T                         84/3016         *NPHP3:* R397H het, S500P het

  JBTS        F256-II1     A229T                         84/3016         *CEP290:* Q1591X het

  BBS         AR74-05      A229T                         84/3016         

  BBS         AR400-03     A229T                         84/3016         

  BBS         AR672-03     A229T                         84/3016         

  BBS         AR775-03     A229T                         84/3016         *MKS1:* D286G het

  BBS         AR348-03     L447S                         0/192           

  BBS         AR623-03     A1183G                        4/192           

  MKS         MKS-060143   R1236C                        0/192           
  -----------------------------------------------------------------------------------------------------------------

###### 

Frequency of *RPGRIP1L* A229T (c.685G\>A; rs61747071) in ciliopathy patients of northern European descent

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinical\               n=        Genotype\   Genotype\   Allele\   Allele\     p-values                                                                                           
  Diagnosis                         Counts      Frequency   Counts    Frequency                                                                                                      
  ----------------------- --------- ----------- ----------- --------- ----------- ---------- ------- --------- -------- ------- ------- -------------- -------------- -------------- --------------
  Controls                1508      1425        82          1         0.945       0.054      0.001   2932      84       0.972   0.028                                                

  NPHP                    66        66          0           0         1           0          0       132       0        1       0                                                    

  MKS                     49        49          0           0         1           0          0       98        0        1       0                                                    

  **Ciliopathy Non-RP**   **115**   **115**     **0**       **0**     1           0          0       **230**   **0**    1       0       **1.92E-03**                  **1.54E-03**   

  LCA                     189       174         14          1         0.921       0.074      0.005   362       16       0.958   0.042                                                

  SLS                     84        75          9           0         0.893       0.107      0       159       9        0.946   0.054                                                

  JBTS                    30        25          5           0         0.833       0.167      0       55        5        0.917   0.083                                                

  BBS                     184       170         14          0         0.924       0.076      0       354       14       0.962   0.038                                                

  **Ciliopathy RP**       **487**   **444**     **42**      **1**     0.912       0.086      0.002   **930**   **44**   0.955   0.045   **6.45E-03**   **7.35E-05**   **0.021**      **1.66E-05**
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Fisher\'s exact test, 1-tailed; 2-tailed p-values remained significant (Ciliopathy Non-RP v. Controls, p=3.84E-03; Ciliopathy RP v. Controls, p=0.013; Ciliopathy Non-RP v. Ciliopathy RP, p=1.47E-04)

Permutation test

###### 

Functional assessment of *RPGRIP1L* missense variants in an *in vivo* zebrafish model

                      Conservation                                               *In vivo* modeling in zebrafish   
  ------------ ------ ---------------------------------------------------------- --------------------------------- ------------
  **S199G**    CCI    *Ptr, Bta, Cfa, Mmu, Oan, Dre*                             pathogenic                        pathogenic
  **A229T**    CCI    *Ptr, Mmul, Eca, Bta, Cfa, Rno, Mmu, Mdo, Dre*             pathogenic                        pathogenic
  **L447S**    CCIV   *Ptr, Mmul*                                                benign                            benign
  **L546F**    CCV    *Ptr, Mmul, Eca, Bta, Cfa, Rno, Mmu, Mdo, Oan, Gga, Dre*   pathogenic                        pathogenic
  **T615P**    C2     *Ptr, Mmul, Eca, Bta, Cfa, Mmu, Mdo*                       pathogenic                        pathogenic
  **V647I**    C2     *Ptr, Mmul, Mdo, Oan, Gga, Dre, Spu*                       pathogenic                        benign
  **T677I**    C2     *Ptr, Mmul, Eca, Bta, Cfa, Rno, Mmu, Oan*                  pathogenic                        pathogenic
  **A695P**    C2     *Ptr, Mmul, Eca, Bta, Cfa, Rno, Mmu, Mdo, Oan, Dre, Spu*   pathogenic                        pathogenic
  **R937L**           *Ptr, Mmul, Cfa*                                           pathogenic                        pathogenic
  **A1183G**   RID    *Ptr, Mmul, Eca, Bta, Cfa, Rno, Mmu, Mdo, Oan, Gga*        pathogenic                        pathogenic
  **R1236C**   RID    *Ptr, Mmul, Eca, Bta, Cfa, Rno, Mmu, Mdo, Oan, Spu*        pathogenic                        pathogenic
  **D1264Y**   RID    *Eca, Bta, Cfa, Rno, Mmu*                                  pathogenic                        pathogenic

CC- Coiled coil domain; C2- protein kinase C (PKC) conserved region 2 motif; RID- domain with homology to the RPGR-interacting domain of RPGRIP1.

Ptr- Pan troglodytes; Mmul- M. mulatta; Eca- E. caballus; Bta- B. taurus; Cfa- C. familiaris; Rno- R. norvegicus; Mmu- M. musculus; Mdo- M. domestica; Oan- O. anatinus; Gga- G. gallus; Dre- D. rerio; Spu- S. purpuratus

[^1]: These authors contributed equally to this work.
